FibroBiologics, Inc. Common Stock (FBLG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.57M
Last updated: Nov 17, 2026 at 11:01 AM ET
FibroBiologics, Inc. Common Stock (FBLG) Financials: Revenue, Profit and Cash Flow
FibroBiologics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Jun 30, 2026. That year, net income was -$18.65M, operating cash flow was -$16.39M and free cash flow was -$16.66M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$4.12M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of $16.65M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $0 | N/A | N/A | N/A | N/A |
| Jun 2025 | $0 | N/A | N/A | N/A | N/A |
| Jun 2024 | $0 | N/A | N/A | N/A | N/A |
| Jun 2023 | $0 | N/A | N/A | N/A | N/A |
| Jun 2022 | $0 | N/A | N/A | N/A | N/A |
| Jun 2021 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
| Cost of revenue | $832.00K | $573.00K | $437.00K | $94.00K | N/A | N/A |
| Gross profit | -$832.00K | -$573.00K | -$437.00K | -$94.00K | N/A | N/A |
| Research and development | $7.41M | $4.50M | $2.37M | $1.15M | $521.00K | $669.00K |
| Operating income | -$16.65M | -$13.74M | -$8.89M | -$4.47M | -$1.58M | -$1.17M |
| Net income | -$18.65M | -$11.16M | -$16.48M | -$5.12M | -$1.58M | -$1.17M |
| EBITDA | N/A | -$10.57M | N/A | -$4.37M | -$1.58M | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $554.00K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | N/A | N/A | -$234.00K | -$231.00K | -$206.00K | N/A | $277.00K | N/A | -$140.00K | -$137.00K | -$130.00K | -$112.00K |
| Operating income | -$4.03M | -$5.07M | -$2.59M | -$5.04M | -$4.49M | -$4.53M | -$3.71M | -$3.35M | -$3.22M | -$3.45M | -$2.48M | -$2.05M |
| Net income | -$4.12M | -$5.00M | -$3.24M | -$5.78M | -$4.66M | -$4.97M | -$3.10M | -$500.00K | $898.00K | -$8.46M | -$9.72M | -$2.19M |
Balance Sheet
As of Jun 2026, cash and equivalents exceeded short-term debt of $706.00K by $4.19M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
| Total assets | $9.62M | $16.45M | $11.82M | $4.82M | $468.00K | N/A |
| Current assets | $6.35M | $14.23M | $9.21M | $2.63M | $468.00K | N/A |
| Cash and equivalents | $4.89M | $13.98M | $9.16M | $2.27M | $407.00K | N/A |
| Total liabilities | $3.46M | $13.71M | $10.57M | $8.82M | $1.76M | N/A |
| Short-term debt | $706.00K | $9.57M | $362.00K | $5.78M | $1.30M | N/A |
| Shareholder equity | $6.16M | $2.73M | $1.25M | -$4.00M | -$1.29M | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.93M | $5.94M | $9.62M | $8.74M | $13.91M | $11.43M | $16.45M | $10.47M | $8.91M | $11.40M | $11.82M | $13.30M |
| Total liabilities | $3.29M | $3.34M | $3.46M | $8.62M | $13.05M | $9.08M | $13.71M | $7.73M | $11.30M | $15.26M | $10.57M | $2.76M |
| Cash and equivalents | $3.52M | $1.48M | $4.89M | $4.87M | $8.85M | $8.67M | $13.98M | $7.83M | $5.97M | $8.16M | $9.16M | $10.77M |
| Shareholder equity | $4.64M | $2.60M | $6.16M | $125.00K | $860.00K | $2.35M | $2.73M | $2.74M | -$2.39M | -$3.86M | $1.25M | $10.54M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2026.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$16.39M | -$11.90M | -$6.40M | -$4.07M | -$1.41M | -$1.17M |
| Capital expenditures | $262.00K | $184.00K | $495.00K | $0 | $0 | $0 |
| Free cash flow | -$16.66M | -$12.09M | -$6.90M | -$4.07M | -$1.41M | -$1.17M |
| Investing cash flow | -$262.00K | -$184.00K | -$495.00K | N/A | N/A | N/A |
| Financing cash flow | $7.57M | $16.91M | $13.79M | $5.92M | $1.82M | $1.17M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.29M | -$4.36M | -$3.16M | -$3.97M | -$3.98M | -$5.28M | -$3.07M | -$2.61M | -$1.95M | -$4.28M | -$1.60M | -$1.14M |
| Capital expenditures | $0 | $0 | $0 | $6.00K | $213.00K | $43.00K | $99.00K | $11.00K | $66.00K | $8.00K | $2.00K | $413.00K |
| Free cash flow | -$3.29M | -$4.36M | -$3.16M | -$3.98M | -$4.20M | -$5.32M | -$3.17M | -$2.62M | -$2.01M | -$4.28M | -$1.60M | -$1.55M |
Frequently Asked Questions About FBLG
What is FibroBiologics, Inc. Common Stock's annual revenue?
FibroBiologics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Jun 30, 2026.
Is FibroBiologics, Inc. Common Stock profitable?
No. FibroBiologics, Inc. Common Stock reported net income of -$18.65M for the fiscal year ended Jun 30, 2026.
How much free cash flow does FBLG generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of -$16.39M minus capital expenditures of $262.00K produced free cash flow of -$16.66M.
How much debt does FibroBiologics, Inc. Common Stock have?
The balance sheet dated Jun 30, 2026 reported short-term debt of $706.00K and cash and equivalents of $4.89M.
FBLG pages: Overview, Earnings, Forecast, Financials, Competitors